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Background: The impact of blood ﬂow regulation and oxidative stress during exercise in cystic ﬁbrosis (CF) has yet to be investigated.
Methods: A maximal graded exercise test was conducted to determine exercise capacity (VO2 peak) and peak workload in 14 pediatric patients
with mild CF (age 14 ± 3 y, FEV1 93 ± 16 % predicted) and 14 demographically-matched controls. On a separate visit, participants performed
submaximal cycling up to 60% of peak workload where brachial artery blood velocity was determined using Doppler ultrasound. Retrograde and
antegrade components were further analyzed as indices of blood ﬂow regulation.
Results: The cumulative AUC for retrograde velocity was lower in patients versus controls (1770 ± 554 vs. 3440 ± 522 cm, P = 0.038). In addition,
an exaggerated oxidative stress response during exercise occurred in patients only (P = 0.004).
Conclusion: These data suggest that patients with mild CF exhibit impaired blood ﬂow regulation and an exaggerated oxidative stress response to
submaximal exercise.
© 2017 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Exercise intolerance; Reactive oxygen species; Retrograde velocity; Electron paramagnetic resonance spectroscopy1. Introduction
Cystic Fibrosis (CF) is an autosomal recessive genetic
disorder that is the result of a mutation in the cAMP-dependent
cystic fibrosis transmembrane conductance regulator (CFTR)-ISO, 8-isoprostane; AOC, antioxidant capacity; CRP,
XA, dual-energy X-ray absorptiometry; EPR, electron
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uropean Cystic Fibrosis Society. Published by Elsevier B.V. Achloride channel protein. There are many systemic complications
in CF which include dysfunction of pulmonary, gastrointestinal,
immune, endocrine, and musculoskeletal systems [1,2]. While
the primary cause of morbidity and mortality in CF is pulmonary
dysfunction and lung infection [3], exercise intolerance is a
hallmark of CF [4,5] and a reduction in maximal aerobic
capacity (VO2 peak) is a significant predictor of mortality in this
patient population, independent of lung function [6,7]. However,
the mechanisms which contribute to exercise intolerance in CF
remain unclear.
The ability to maintain adequate oxygen delivery to the working
musculature is of critical importance, particularly under conditions
of increased demand, such as during exercise. Both macro- and
micro-vascular endothelial dysfunction is present in patients withll rights reserved.
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theworkingmusculature during exercisemay contribute to exercise
intolerance [10,11]. In fact, the pattern of brachial artery flow
during lower limb cycling can provide valuable information re-
garding appropriate exercise induced vasodilatory/vasoconstrictor
responses [12]. While a previous study demonstrated similar
forearm blood flow responses during handgrip exercise in patients
with CF versus healthy counterparts [13], whether or not 1) patients
with CF exhibit abnormal blood flow regulation during exercise of
large muscle-mass or 2) dysfunctional blood flow regulation affects
exercise capacity in this patient population remains unknown.
There is convincing evidence to indicate the presence of chronic
oxidative stress in patients with CF [14,15]. Oxidative stress
in its basic form represents an imbalance between free radical
production and neutralization of radicals by antioxidants and has
been suggested to contribute to the multi-organ pathophysiology
[14] and decline in pulmonary function over time in CF [16].
Oxidative stress is related to exercise capacity in several patient
populations [17,18] and may partly be linked to pancreatic
insufficiency and the intestinal malabsorption of endogenous
fat-soluble vitamins and antioxidants in CF [19]. However,
whether or not oxidative stress impacts exercise capacity in
patients with CF is unknown.
While exercise intolerance in CF is related to a number of
factors, the degree to which blood flow regulation and oxidative
stress influences maximal exercise capacity in CF is unknown.
Therefore, this study sought to test the hypotheses that 1) blood
flow regulation during submaximal cycling exercise is compro-
mised in patients with CF compared to controls, and 2) patients
with CF exhibit an exaggerated increase in oxidative stress during
exercise compared to controls.
2. Materials and methods
2.1. Participants
A total of 28 volunteers (14 patients with CF and 14 healthy
controls) ages 8–20 years old participated in this study. Patients
were enrolled if they had a clinical diagnosis of CF based on
positive sweat test metrics and genotype analysis. Based on
the patients' characteristics, demographically-matched apparently
healthy controls were recruited. Detailed exclusion criteria can be
found in the online supplement. All study protocols were approved
by the Institutional Review Board at Augusta University and
written and verbal assent/consent was obtained by all participants
and parents prior to participation.
2.2. Experimental design
All participants reported for two days of testing; a preliminary
and an experimental visit. The preliminary visit consisted of
the informed consent process, body composition assessments,
a baseline pulmonary function test (PFT), and a maximal exercise
capacity test. On the experimental visit, a second PFT was
performed prior to beginning the submaximal exercise protocol.
Brachial artery diameter and blood velocity were measured
while sitting on a cycle ergometer at baseline and duringsubmaximal cycling exercise at 20, 40 and 60% of peak
workload. Blood samples were taken at baseline and at 60%
intensity for assessment of oxidative stress biomarkers. Patients
were instructed to adhere to the timing of their daily treatments
and report to the laboratory following their morning airway
clearance technique and inhaled medicine regimen.
2.3. Participant characteristics and clinical laboratory values
Participant testing included assessments of height, weight,
calculated body mass index (BMI), and body composition
via dual-energy X-ray absorptiometry (DXA; QDR-4500 W;
Hologic, Waltham, MA). An estimate of daily physical activity
levels was determined from a self-reported health-history ques-
tionnaire. Blood pressure was measured in triplicate according
to American Heart Association recommendations. Concentrations
of total cholesterol (TC), high-density lipoproteins (HDL), low-
density lipoproteins (LDL), triglycerides (TG), glucose, and
high sensitivity C-reactive protein (hsCRP) were obtained using
a Cholestech LDX point of care analyzer (Alere Inc., Scarborough,
ME). Hemoglobin and hematocrit were obtained using a
HemoPoint H2 analyzer (Stanbio Laboratory, Boerne, TX).
2.4. Pulmonary function testing
Pulmonary function testing (PFT) was performed in all
participants using closed circuit spirometry (ParvoMedics, Sandy,
UT) according to the American Thoracic Society standards [20] to
determine forced expiratory volume in 1 second (FEV1), forced
vital capacity (FVC), FEV1/FVC ratio, and forced expiratory flow
at 25–75% (FEF25–75). The national health and nutrition
examination survey (NHANES) III spirometric reference standards
were used to determine the percent predicted data outcomes.
2.5. Maximal exercise capacity
On the preliminary visit, maximal exercise capacity (VO2
peak) was determined on a cycle ergometer using the Godfrey
Protocol [21]. Briefly, participants pedaled on an appropriate
sized electronically braked cycle ergometer (Lode Corival or
Lode Corival Pediatric, Groningen, Netherlands) with work
intensities increasing every minute until volitional fatigue,
breathlessness, chest discomfort, and/or any other signs observed
by the investigators that the test should be terminated. Throughout
maximal exercise testing, breath by breath expired gases were
analyzed by a TruOne® 2400 metabolic cart (ParvoMedics,
Sandy, UT) and reported as 30 s averages to obtain VO2 peak.
Heart rate, blood pressure, and SpO2 were monitored throughout
the test.
2.6. Submaximal exercise
On the experimental visit (at least one week following pre-
liminary testing), all participants performed submaximal exercise
on a cycle ergometer at 20, 40, and 60% of the maximum
workload (Watts) that was obtained from themaximal exercise test.
Following a 2 min unloaded warm-up, each workload intensity
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tinuous submaximal exercise.2.7. Brachial artery diameter, blood velocity, and shear rate
Blood flow regulation was determined by assessing changes
in brachial artery diameter, blood flow, and blood velocity
during increasing exercise intensity. At baseline and during
submaximal exercise at 20, 40, and 60% intensity, assessment
of brachial artery diameter and velocity was determined using
Doppler ultrasound (LOGIQ 7, General Electric Company,
Chicago, IL). Further details on the ultrasound methodology
used can be found in the online supplement.Table 1
Participant characteristics and clinical laboratory values.
Variable Controls CF P value
Demographics
N 14 14
Sex (M/F) 6/8 6/8
Age (y) 14 ± 3 14 ± 3 0.905
Height (cm) 158 ± 18 156 ± 17 0.784
Weight (kg) 49.7 ± 13.8 46.9 ± 14.3 0.597
BMI (kg/m2) 19.7 ± 2.9 18.7 ± 2.0 0.333
Body Fat (%) 23.7 ± 8.4 19.8 ± 6.0 0.1772.8. Oxidative stress and free radical biomarkers
Antioxidant capacity (AOC) and 8-isoprostane (8-ISO) were
determined from plasma via colorimetric assay following the
manufacturer's instructions (Cayman Chemical, Ann Arbor, MI).
Details on methods used to determine plasma trolox-equivalent
antioxidant capacity (TEAC), ferric reducing antioxidant poten-
tial (FRAP), plasma lipid hydroperoxides (LPO), and protein
carbonyls (PC) can be found in the online supplement.
Electron Paramagnetic Resonance (EPR) spectroscopy was
used to determine alkoxyl and ascorbyl free radicals as previously
described [22]. Comprehensive details on the EPR methodology
used can be found in the online supplement. Due to technical
difficulties, not all participants' samples were analyzed. Data
comparing oxidative stress and free radical biomarkers are
presented with a minimum sample of nine participants per group.SBP (mm Hg) 107 ± 16 104 ± 12 0.553
DBP (mm Hg) 63 ± 9 61 ± 6 0.452
Resting O2 saturation (%) 98.8 ± 0.4 98.2 ± 0.7 0.035
Pulmonary function
FVC (L) 3.80 ± 1.27 3.58 ± 1.42 0.668
FEV1 (L) 3.36 ± 1.08 2.91 ± 1.29 0.339
FEV1 (% predicted) 104 ± 12 93 ± 16 0.038
FEV1/FVC (%) 89 ± 7 80 ± 7 0.004
FEF25–75 (L/s) 4.0 ± 1.5 2.9 ± 1.4 0.044
Exercise capacity
VO2 peak (ml/kg/min) 36.4 ± 8.9 33.0 ± 6.2 0.252
VO2 peak (ml/kg-FFM/min) 50.4 ± 7.6 43.7 ± 6.8 0.022
VO2 peak (% predicted) 85 ± 16 74 ± 12 0.054
Peak work (W) 149 ± 56 122 ± 44 0.165
Clinical laboratory markers
TC (mg/dl) 149 ± 27 122 ± 25 0.013
HDL (mg/dl) 54 ± 11 36 ± 13 0.001
LDL (mg/dl) 83 ± 20 69 ± 20 0.119
Triglycerides (mg/dl) 71 ± 27 82 ± 31 0.351
Glucose (mg/dl) 85 ± 8 91 ± 11 0.149
TC:HDL 2.8 ± 0.6 3.8 ± 1.8 0.072
hsCRP (mg/l) 0.4 ± 0.2 1.6 ± 1.8 0.032
Hemoglobin (g/dl) 13.9 ± 1.4 13.5 ± 1.3 0.372
Hematocrit (%) 41.0 ± 4.1 40.5 ± 3.1 0.766
Values are mean ± SD. Bold face indicates significance. BMI = bodymass index;
SBP = systolic blood pressure; DBP = diastolic blood pressure; FVC = forced
vital capacity; FEV1 = forced expiratory volume in 1 s; FEF = forced expiratory
flow; VO2 = volume of oxygen consumed; TC = total cholesterol; HDL = high
density lipoprotein; LDL = low density lipoprotein; hsCRP = high sensitivity
C-reactive protein.2.9. Statistical analyses
All analyses were performed using SPSS version 23 (IBM
Corporation, Somers, NY). Descriptive statistics were generated
and range as well as normality checks performed. Two-way
repeated measures ANOVA (group x time) were used to test
for group differences in blood flow regulation and changes
in oxidative stress markers during exercise. The Greenhouse-
Geisser correction was applied when the assumption of sphe-
ricity was violated and follow up pairwise comparisons were
performed and adjusted for multiple comparisons using a
Bonferroni correction. Effect sizes (partial eta squared [ηP
2]) are
reported for the interaction terms of the ANOVA, where values
of 0.01, 0.06, and 0.14 correspond to small, medium, and large
effects, respectively [23]. Comparisons of participant charac-
teristics, baseline values of oxidative stress markers, and area
under the curve (AUC) values between groups were performed
using independent t-tests or Mann-Whitney U tests if data were
not normally distributed. Pearson product-moment correla-
tions were used to examine relationships between blood flow
regulation, exercise capacity, and oxidative stress. An alpha
b0.05 was considered statistically significant for all analyses.
Data are presented as mean ± standard deviation (SD) unless
stated otherwise.3. Results
3.1. Participant characteristics and clinical laboratory values
Estimated habitual daily physical activity was not different
between groups (P N 0.05). Participant characteristics and clinical
laboratory values are presented in Table 1. There were no
differences in age, height, weight, BMI, LDL, TG, TC:HDL
ratio, fasting glucose, hematocrit, hemoglobin, or blood pressure
between patients and controls. Resting SpO2 and lung function
values (FEV1 % predicted, FEV1/FVC, and FEF25–75) were all
lower in patients versus controls. Importantly, the pulmonary
function values are representative of a relatively healthy and mild
disease patient cohort [24]. All pulmonary function values during
the preliminary and experimental visits were similar (P N 0.05;
intra-class correlations [ICC] N0.903; P b 0.001). Although exer-
cise capacity expressed relative to body mass was similar between
groups, it was significantly lower in patients when expressed rel-
ative to fat-free mass. Differences in exercise capacity (expressed
as % predicted) between groups was approaching significance
Fig. 1. Retrograde (Panel A) and antegrade (Panel B) blood velocity at baseline,
and during sub-maximal exercise at 20, 40, and 60% of VO2 peak in controls
(n = 14) and patients with CF (n = 14). *significant difference in total AUC
between groups (P b 0.05).
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was observed between groups.
Both TC and HDL were higher in controls when compared
to patients. A 3-fold higher concentration of hsCRP was also
observed in patients with CF compared to controls.
3.2. Brachial artery hemodynamics
Brachial artery hemodynamics at rest and during submax-
imal exercise are presented in Table 2.
3.2.1. Brachial artery diameter, mean blood velocity, and blood
ﬂow
Brachial artery diameter (cm) did not change over time
(P = 0.471), nor was there a main effect of group (P = 0.897)
or a significant group × time interaction (P = 0.293, ηP
2 =
0.042). Mean velocity (cm/s) increased over time (P b 0.001);
however, the group x time interaction was not significant (P =
0.119, ηP
2 =0.079). Overall, mean velocity at 40% and 60%
intensity was higher (P b 0.001) compared to both 20% inten-
sity and baseline values. In addition, there was a main effect of
group, such that mean velocity was lower in patients (9.4 ±
1.2 cm/s) compared to controls (13.0 ± 1.2 cm/s, P = 0.043).
Blood flow (ml/min) increased over time (P b 0.001) but
the group x time interaction was not significant (P = 0.089,
ηP
2=0.091). Across groups, mean blood flow at 20% intensity
was not different versus baseline (P = 0.881) but progressively
increased during exercise. Specifically, mean blood flow at 60%
intensity was higher versus all other time points (P b 0.01) and
40% intensity was higher compared to both 20% intensity and
baseline values (P b 0.01).
3.2.2. Retrograde and Antegrade blood velocity and blood ﬂow
Fig. 1A illustrates the significant (P = 0.030, ηP
2=0.128)
group × time interaction for retrograde velocity. Specifically, the
total AUC for retrograde velocity was lower in patients versus
controls (P = 0.038). Retrograde blood flow (ml/min) increased
over time (P b 0.001) but the group x time interaction was not
significant (P = 0.130, ηP
2=0.078; Table 2). Overall, retrograde
blood flow increased progressively such that it was higher at each
successive exercise intensity (all P b 0.01) with the exceptionTable 2
Blood flow variables at rest and during exercise at 20, 40, and 60% intensity.
Baseline 20%
Variable Controls CF Controls C
Diameter (cm) 0.28 ± 0.05 0.28 ± 0.05 0.28 ± 0.05 0
Mean velocity (cm/s) 9.3 ± 4.4 5.8 ± 1.4 8.6 ± 4.6 7
Blood flow (ml/min) 34.4 ± 19.1 21.8 ± 9.3 29.0 ± 13.4 2
Retrograde blood flow (ml/min) 2.8 ± 4.1 4.4 ± 6.8 10.3 ± 12.6 ‡ 1
Antegrade blood flow (ml/min) 37.0 ± 20.5 26.3 ± 12.1 38.7 ± 17.6 ‡ 3
Mean shear rate (s−1) 171 ± 54 277 ± 141 231 ± 62 2
Heart rate (bpm) 82 ± 10 76 ± 11 100 ± 9 1
Values are mean ± SD.
⁎ Signiﬁcantly higher versus baseline and 20% intensity, independent of group (P
† Signiﬁcantly higher versus baseline, 20%, and 40% intensity, independent of gr
‡ Signiﬁcantly higher versus baseline, independent of group (P b 0.01).
# Signiﬁcantly higher versus controls within same level of intensity (P = 0.017).of a non-significant difference between 40% and 60% intensity
(P = 0.242).
Antegrade velocity (cm/s) increased over time (P b 0.001)
but the group x time interaction was not significant (P = 0.225,
ηP
2=0.055; Fig. 1B). Moreover, the total AUC for antegrade
velocity was similar between groups (P = 0.147). Antegrade
blood flow (ml/min) increased over time (P b 0.001) but the
group x time interaction was not significant (P = 0.322, ηP
2=
0.043). Overall, antegrade blood flow increased progressively
such that it was significantly higher at each successive exercise
intensity (all P b 0.01).40% 60%
F Controls CF Controls CF
.27 ± 0.05 0.28 ± 0.05 0.27 ± 0.05 0.28 ± 0.05 0.27 ± 0.05
.8 ± 2.2 15.3 ± 9.6 ⁎ 10.2 ± 3.7 ⁎ 18.9 ± 8.4 ⁎ 13.7 ± 4.4 ⁎
8.0 ± 13.2 54.5 ± 35.4 ⁎ 36.1 ± 15.8* 71.4 ± 38.1 † 49.4 ± 19.2 †
1.0 ± 9.4 ‡ 12.5 ± 15.4 ⁎ 19.8 ± 15.8 ⁎ 14.3 ± 17.7 ⁎ 23.6 ± 17.1 ⁎
9.8 ± 17.3 ‡ 63.9 ± 32.8 ⁎ 56.0 ± 25.2 ⁎ 80.2 ± 37.7 † 73.1 ± 29.8 †
66 ± 166 305 ± 131 ⁎ 458 ± 297 ⁎ 412 ± 166 † 554 ± 254 †
01 ± 11 118 ± 16 127 ± 16 139 ± 19 157 ± 17 #
b 0.05).
oup (P b 0.05).
Fig. 2. PBN-adduct at baseline and during sub-maximal exercise at 60% VO2
peak in controls (n = 9) and patients with CF (n = 11). *significantly different
from controls at 60% (P = 0.005); †significant change from baseline in patients
with CF (P = 0.001).
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Mean shear rate (s−1) increased over time (P b 0.001) but
the group x time interaction was not significant (P = 0.183,
ηP
2=0.063; Table 2). Overall, mean shear rate at 20% intensity
was not different versus baseline (P = 0.263); however, it was
higher at each successive exercise intensity (all P b 0.01).
A significant group x time interaction (P = 0.001, ηP
2=0.278)
was present for changes in heart rate. Specifically, heart rate was
higher in patients at 60% intensity versus controls (P = 0.017).
No differences between groups were observed at baseline (P =
0.133), 20% (P = 0.756), or 40% intensity (P = 0.180).
3.3. Oxidative stress biomarkers
Oxidative stress biomarkers at rest and during exercise are
presented in Table 3. A significant group x time interaction
was present for alkoxyl free radical (a-phenyl-tert-butylnitrone
[PBN] adduct, P = 0.004, ηP
2 =0.382). Specifically, alkoxyl
free radical was higher during exercise in patients versus
controls (P = 0.005; Fig. 2). No differences in baseline
concentrations of ascorbyl free radical, AOC, 8-ISO, FRAP,
TEAC, PC, or LPO were present between groups
(all P N 0.05). Changes in additional markers of oxidative
stress from baseline to exercise were not dependent on group
(i.e., no significant interactions [all P N 0.05]). Independent of
group, there was a main effect of time for AOC as it decreased
following exercise (P = 0.008). No significant main effect of
time was present for ascorbyl free radical (P = 0.083), 8-ISO
(P = 0.085), or FRAP (P = 0.079).
3.4. Relationships between blood ﬂow regulation, exercise
capacity, and oxidative stress
Fig. 3A illustrates the significant relationship (r = 0.454,
P = 0.015) between the change (Δ) in retrograde velocity duringTable 3
Oxidative stress biomarkers at rest and during exercise at 60% intensity.
Baseline Exercise
Variable Controls CF Controls CF
Ascorbyl FR × 103
(a.u.) a
650 ± 205 669 ± 501 874 ± 301 2198 ± 2811
AOC (mM) b 1.34 ± 0.34 1.43 ± 0.50 1.13 ± 0.29 f 1.12 ± 0.49⁎
8-ISO (ng/ml) c 16.2 ± 10.7 16.0 ± 7.8 17.1 ± 9.6 24.5 ± 20.1
FRAP (μmol/l) b 0.64 ± 0.21 0.69 ± 0.24 0.72 ± 0.09 0.77 ± 0.11
TEAC (μmol/l) b 0.43 ± 0.14 0.41 ± 0.14 0.46 ± 0.03 0.46 ± 0.08
PC (μmol/mg
protein) d
0.45 ± 0.04 0.39 ± 0.13 0.45 ± 0.05 0.44 ± 0.11
LPO (μmol/l) e 0.55 ± 0.55 0.78 ± 0.54 0.79 ± 0.75 0.69 ± 0.55
Values are mean ± SD. FR = free radicals; AOC = antioxidant capacity;
8-ISO = 8-isoprostane; FRAP = ferric reducing antioxidant power; TEAC =
trolox equivalent antioxidant capacity; PC = protein carbonyls; LPO = lipid
hydroperoxide.
a Controls (n = 9), CF (n = 9).
b Controls (n = 12), CF (n = 14).
c Controls (n = 12), CF (n = 11).
d Controls (n = 10), CF (n = 10).
e Controls (n = 11), CF (n = 13).
f Main effect of time, independent of group (P = 0.008).exercise and exercise capacity (VO2 peak,% predicted). Similarly,
the relationship between Δ retrograde velocity and peak workload
(Watts) was significant, both overall (r = 0.551, P = 0.024) and
when only examining patients with CF (r = 0.604, P = 0.011,
n = 14). In addition, there was an overall significant negative
relationship (r = −0.481, P = 0.032) between Δ retrograde
velocity and the change in oxidative stress during exercise
(ΔPBN adduct; Fig. 3B).
4. Discussion
A number of factors contribute to exercise intolerance in
patients with CF including pulmonary dysfunction [5], impaired
skeletal muscle function [25], and impaired oxygen uptake kinetics
[26]. However, whether or not alterations in blood flow andFig. 3. Significant relationships between A) basal exercise capacity (VO2 peak,
% predicted) and the change in retrograde velocity, and B) the change in
oxidative stress during exercise and the change in retrograde velocity.
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particularly in patients with mild disease severity (such as the
pediatric patients tested in the present study). For the first time,
this investigation provides compelling evidence to indicate that,
compared to controls, younger patients with CF have impaired
blood flow regulation during submaximal exercise that is ac-
companied by an exaggerated increase in oxidative stress during
exercise. In addition, our data suggest a potential link between
impaired blood flow regulation, exercise-induced oxidative stress,
and exercise capacity.
4.1. Impaired blood ﬂow regulation during exercise in CF
During exercise that involves a largemuscle mass (i.e., cycling),
the demand for adequate nutrient supply to the working mus-
culature results in a peripheral (i.e., upper body) vasoconstrictor
response [27,28]. In the present study, we identified a substantial
difference in brachial artery retrograde velocity during submaximal
exercise between patients and controls (Fig. 1A), suggestive of an
inadequate upper body vasoconstrictor response in patients. While
there were no differences in retrograde velocity at baseline or
the lightest exercise intensity (20%) between groups, as exercise
intensity increased, retrograde velocity appeared to plateau in
patients with CF, whereas an increased trajectory was observed
in controls. Interestingly, our findings are in contrast to a previ-
ous investigation investigating forearm blood flow responses to
handgrip exercise in patients with CF [13], although differences
between studies may be partly due to exercise modality and
intensity. No group differences up to 15% of maximal grip strength
were observed previously [13] and data from the present study
show a sizeable separation between groups beginning at 40%
intensity (Fig. 1A). Taken together, data from both studies seem to
indicate that differences in exercise blood flow responses between
patients with CF and controls may only be evident at higher
workloads.
Given that retrograde velocity of the brachial artery during
cycling is representative of the peripheral vasoconstrictor response
in a non-exercising limb, the appropriate response (as observed in
controls) should be a stepwise escalation in retrograde velocity as
lower leg exercise intensity increases [29]. The lack of increase
in retrograde velocity in young patients with CF suggests an
abnormal pattern of blood flow during exercise, likely resulting in
reduced blood flow to the working muscle and contributing to
a lower exercise capacity. Impaired blood flow regulation can
induce additional physiological strain which is evidenced by the
higher heart rate in patients versus controls at 60% exercise
intensity (Table 2), likely in an effort to increase cardiac output
and maintain sufficient blood flow to the working muscle. While
we did not measure femoral artery blood flow in the present study,
previous studies have shown that reduced blood flow to the
working musculature limits exercise capacity in healthy [30] and
clinical populations [10,11]. Moreover, our data suggest that a
greater increase in retrograde velocity is significantly related to a
higher exercise capacity (Fig. 3A). Thus, these data collectively
suggest that impaired blood flow regulation may contribute to
exercise intolerance in CF. Future studies should measure blood
flow to the working musculature during exercise to confirm thefindings of the present study that suggest this may be reduced in
patients with CF.4.2. Oxidative stress during exercise impacts blood ﬂow regulation
in CF
Interpretation of exercise-induced oxidative stress responses
are challenging due to multiple ROS sources, endogenous radical
quenching compounds, and confounding effects of chronic disease
conditions [31], including CF. Unequivocal evidence indicates
that patients with CF exhibit an elevated basal oxidative stress
profile [14,15]; however, the oxidative stress response to exercise
and its potential role in augmenting blood flow regulation and
limiting exercise capacity in this population is unknown. Given
the preserved clinical presentation of the pediatric patients with
CF recruited for this investigation, it is not surprising that basal
markers of oxidative stress were similar between patients and
controls (Table 3). Perhaps more importantly, the free radical
response to sub-maximal exercise was markedly increased in
patients with CF compared to controls (Fig. 2). The disparity in
the free radical response between groups could be due to different
endogenous antioxidant buffering capacities during exercise.
Interestingly, the changes in different markers of antioxidant
activity (i.e., AOC, FRAP, TEAC) during exercise were similar
between groups, which may suggest that the antioxidant defence
system per se in patients with CF is preserved, yet is overloaded
by the excessive ROS production during exercise. Patients with
CF may benefit from exogenous antioxidant supplementation
as a means to enhance free radical buffering and improve exer-
cise capacity, particularly as benefits of this therapy have been
reported in other clinical populations with a similar phenotype as
CF [32,33].
Unique to the present investigation, there appeared to be a
negative association between changes in oxidative stress and
retrograde velocity (Fig. 3B). These data suggest the possibility
that exercise-induced oxidative stress, in part, may contribute to
impaired blood flow regulation. Conceptually, there are many
ways to link oxidative stress to impaired blood flow regulation;
however, one of the key mediators of blood flow is vascular tone
and NO production [34]. Moreover, while there are disparate
findings regarding the role of NO in exercise hyperemia [35,36],
previous work has shown that NO contributes significantly to
blood flow in a non-exercising limb during lower limb cycling
exercise [12]. It is well established that the superoxide anion
can limit the bioavailability of NO and our group has described
both macro- [8] and micro- vascular [9] endothelial dysfunction in
patients with CF. Although the present study was not designed to
specifically examine the role of endothelial function on blood
flow regulation, it is plausible that the increased oxidative stress
contributed to vascular dysfunction and subsequent impairment in
blood flow regulation during exercise. Nonetheless, future studies
are warranted to evaluate changes in blood flow regulation
following interventions that improve endothelial function, and
further investigate the interactions between endothelial function,
oxidative stress, and blood flow regulation during exercise in
patients with CF.
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The observation of exercise intolerance in patients with CF is
due to a variety of complications associated with the disease. Data
from the present study highlight the importance of appropriate
regulation of blood flow during exercise in this patient population
and provide a link between exercise-induced oxidative stress
and exercise capacity in CF. Accordingly, therapies that target
blood flow regulation and oxidative stress in CF may yield an
improvement in exercise capacity, subsequently increasing quality
of life and survival in this patient group.
Interestingly, these findings were in a young cohort of
patients with well-preserved lung function. While not statistically
significant, disease severity (FEV1, % predicted) appears to
be negatively associated with the change in oxidative stress
(PBN adduct) during exercise in patients with CF (r = −0.501,
P = 0.116). These data provide insight into the role that disease
severity may play in mediating the oxidative stress response to
exercise and, subsequently, exercise capacity in patients with
moderate to severe disease severity. Future studies should seek to
examine blood flow and oxidative stress responses to exercise in
patients with CF at more advanced stages of the disease.4.4. Conclusions
The present investigation provides unique evidence of im-
paired blood flow regulation during sub-maximal exercise in
pediatric patients with CF, which may be partially mediated by an
exaggerated, exercise-induced oxidative stress response. Addi-
tionally, dysfunctional blood flow regulation during exercise
may be associated with exercise capacity and oxidative stress in
CF, although further investigation is needed to confirm these
observations. Impaired blood flow regulation and the exaggerated
oxidative stress response to exercise provides two potential
mechanisms that may be contributing to exercise intolerance in
patients with CF. Since exercise capacity predicts mortality in
patients with CF, future studies are warranted to identify
interventions that may increase survival rates by improving blood
flow regulation and reducing oxidative stress during exercise.Competing interests
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